Drug Approval | May 04, 2022
Eugia Pharma receives USFDA approval for Bortezomib
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Docosanol Cream, 10% (OTC) has an estimated market size of US$60 million for twelve months ending December 2021 according to IQVIA
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
The announcement follows FDA 510(k) clearance of device
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
The inspection was triggered by Shilpa's submission of applications for four ANDA's to seek approval to use this site as an alternate testing laboratory
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Subscribe To Our Newsletter & Stay Updated
